Virtus ETF Advisers LLC Has $74,000 Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

Virtus ETF Advisers LLC boosted its position in shares of Silence Therapeutics plc (NASDAQ:SLN) by 130.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,772 shares of the company’s stock after purchasing an additional 6,098 shares during the period. Virtus ETF Advisers LLC’s holdings in Silence Therapeutics were worth $74,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Barclays PLC grew its holdings in Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after purchasing an additional 2,793 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Silence Therapeutics during the fourth quarter valued at approximately $26,000. GAMMA Investing LLC grew its holdings in Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Silence Therapeutics during the fourth quarter valued at approximately $69,000. Finally, FNY Investment Advisers LLC acquired a new position in Silence Therapeutics during the fourth quarter valued at approximately $120,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. The Goldman Sachs Group lowered their price target on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a report on Tuesday, March 4th. BMO Capital Markets lowered their price target on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Friday, March 7th. Finally, Morgan Stanley dropped their target price on shares of Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.67.

Silence Therapeutics Trading Up 4.2 %

Shares of SLN stock opened at $3.50 on Tuesday. Silence Therapeutics plc has a 1 year low of $1.97 and a 1 year high of $24.38. The firm’s fifty day simple moving average is $3.56 and its 200 day simple moving average is $7.32. The firm has a market capitalization of $104.76 million, a P/E ratio of -2.23 and a beta of 1.25.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.